Does the media prefer AMRX or PAHC?

In the previous week, Phibro Animal Health had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Phibro Animal Health and 11 mentions for Amneal Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.61 beat Amneal Pharmaceuticals' score of 0.49 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PAHC or DFTX?

In the previous week, Definium Therapeutics had 29 more articles in the media than Phibro Animal Health. MarketBeat recorded 43 mentions for Definium Therapeutics and 14 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.61 beat Definium Therapeutics' score of 0.34 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 8 Very Positive mention(s) 10 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 5 Very Negative mention(s) Neutral

Does the media prefer PAHC or MANE?

In the previous week, Phibro Animal Health had 13 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Phibro Animal Health and 1 mentions for Veradermics. Phibro Animal Health's average media sentiment score of 0.61 beat Veradermics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INDV or PAHC?

In the previous week, Phibro Animal Health had 10 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Phibro Animal Health and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Phibro Animal Health's score of 0.61 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PAHC or OGN?

In the previous week, Phibro Animal Health had 12 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Phibro Animal Health and 2 mentions for Organon & Co.. Phibro Animal Health's average media sentiment score of 0.61 beat Organon & Co.'s score of 0.51 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Phibro Animal Health (PAHC) Competitors

$34.56 +0.12 (+0.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$34.52 -0.04 (-0.10%)

As of 09/18/2026 07:30 PM Eastern

Compare

PAHC vs. AMRX, DFTX, MANE, INDV, and OGN

Should you buy Phibro Animal Health stock or one of its competitors? Phibro Animal Health's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), and Organon & Co. (OGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Phibro Animal Health (NASDAQ:PAHC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Amneal Pharmaceuticals currently has a consensus target price of $20.14, suggesting a potential upside of 7.66%. Phibro Animal Health has a consensus target price of $47.67, suggesting a potential upside of 37.92%. Given Phibro Animal Health's higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Phibro Animal Health has a net margin of 6.57% compared to Amneal Pharmaceuticals' net margin of 5.05%. Phibro Animal Health's return on equity of 37.86% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Phibro Animal Health	6.57%	37.86%	9.18%

Phibro Animal Health has lower revenue, but higher earnings than Amneal Pharmaceuticals. Phibro Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18
Phibro Animal Health	$1.52B	0.92	$99.72M	$2.44	14.16

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

In the previous week, Phibro Animal Health had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Phibro Animal Health and 11 mentions for Amneal Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.61 beat Amneal Pharmaceuticals' score of 0.49 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phibro Animal Health beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Definium Therapeutics?

Phibro Animal Health (NASDAQ:PAHC) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Phibro Animal Health has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	0.92	$99.72M	$2.44	14.16
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Phibro Animal Health presently has a consensus target price of $47.67, indicating a potential upside of 37.92%. Definium Therapeutics has a consensus target price of $64.88, indicating a potential upside of 67.16%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 29 more articles in the media than Phibro Animal Health. MarketBeat recorded 43 mentions for Definium Therapeutics and 14 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.61 beat Definium Therapeutics' score of 0.34 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	8 Very Positive mention(s)	10 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Neutral

Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.57% compared to Definium Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Definium Therapeutics	N/A	-84.01%	-63.66%

Summary

Phibro Animal Health beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Veradermics?

Phibro Animal Health (NASDAQ:PAHC) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Phibro Animal Health has a net margin of 6.57% compared to Veradermics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Veradermics	N/A	N/A	N/A

Phibro Animal Health has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	0.92	$99.72M	$2.44	14.16
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Phibro Animal Health currently has a consensus price target of $47.67, indicating a potential upside of 37.92%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 42.77%. Given Veradermics' stronger consensus rating and higher possible upside, analysts plainly believe Veradermics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Phibro Animal Health had 13 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Phibro Animal Health and 1 mentions for Veradermics. Phibro Animal Health's average media sentiment score of 0.61 beat Veradermics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Phibro Animal Health beats Veradermics on 11 of the 14 factors compared between the two stocks.

How does Phibro Animal Health compare to Indivior?

Indivior (NASDAQ:INDV) and Phibro Animal Health (NASDAQ:PAHC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Indivior has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Phibro Animal Health had 10 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Phibro Animal Health and 4 mentions for Indivior. Indivior's average media sentiment score of 1.04 beat Phibro Animal Health's score of 0.61 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has a net margin of 26.65% compared to Phibro Animal Health's net margin of 6.57%. Phibro Animal Health's return on equity of 37.86% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Phibro Animal Health	6.57%	37.86%	9.18%

Indivior currently has a consensus target price of $45.17, indicating a potential upside of 29.49%. Phibro Animal Health has a consensus target price of $47.67, indicating a potential upside of 37.92%. Given Phibro Animal Health's higher possible upside, analysts clearly believe Phibro Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Indivior has higher earnings, but lower revenue than Phibro Animal Health. Indivior is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Phibro Animal Health	$1.52B	0.92	$99.72M	$2.44	14.16

Summary

Indivior beats Phibro Animal Health on 9 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Organon & Co.?

Phibro Animal Health (NASDAQ:PAHC) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Phibro Animal Health had 12 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Phibro Animal Health and 2 mentions for Organon & Co.. Phibro Animal Health's average media sentiment score of 0.61 beat Organon & Co.'s score of 0.51 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	0.92	$99.72M	$2.44	14.16
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.77

Phibro Animal Health has a net margin of 6.57% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Phibro Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Organon & Co.	3.41%	88.97%	6.03%

Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Phibro Animal Health pays an annual dividend of $0.48 per share and has a dividend yield of 1.4%. Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Phibro Animal Health pays out 19.7% of its earnings in the form of a dividend. Organon & Co. pays out 10.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Phibro Animal Health presently has a consensus price target of $47.67, indicating a potential upside of 37.92%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 16.70%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Phibro Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Phibro Animal Health beats Organon & Co. on 12 of the 18 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.40B	$12.48B	$7.26B	$13.14B
Dividend Yield	1.39%	2.63%	2.57%	12.30%
P/E Ratio	14.16	797.25	275.79	25.40
Price / Sales	0.92	950.97	695.58	114.44
Price / Cash	7.53	88.44	77.42	51.66
Price / Book	3.64	10.53	10.46	6.33
Net Income	$99.72M	$2.82B	$3.49B	$358.33M
7 Day Performance	-2.98%	1.69%	0.59%	1.12%
1 Month Performance	-2.48%	0.83%	-2.01%	-2.67%
1 Year Performance	-13.30%	3.90%	18.09%	6.01%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.1649 of 5 stars	$34.56 +0.3%	$47.67 +37.9%	-14.8%	$1.40B	$1.52B	14.16	2,605	Trending News Analyst Revision High Trading Volume
AMRX Amneal Pharmaceuticals	3.3675 of 5 stars	$16.65 -3.3%	$19.57 +17.5%	+90.7%	$5.32B	$3.02B	33.98	8,500	Trending News Analyst Forecast
DFTX Definium Therapeutics	3.0633 of 5 stars	$36.82 -8.5%	$64.88 +76.2%	+309.4%	$4.95B	N/A	N/A	40	Analyst Forecast
MANE Veradermics	2.0067 of 5 stars	$104.15 +2.4%	$153.00 +46.9%	N/A	$4.35B	N/A	N/A	21	Positive News Analyst Forecast
INDV Indivior	4.0806 of 5 stars	$34.22 -0.7%	$45.17 +32.0%	+52.4%	$4.04B	$1.33B	12.27	838	News Coverage Positive News Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. AMRX, DFTX, MANE, INDV, and OGN

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Summary

How does Phibro Animal Health compare to Definium Therapeutics?

Summary

How does Phibro Animal Health compare to Veradermics?

Summary

How does Phibro Animal Health compare to Indivior?

Summary

How does Phibro Animal Health compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. AMRX, DFTX, MANE, INDV, and OGN

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Do analysts prefer AMRX or PAHC?

Is AMRX or PAHC more profitable?

Which has better valuation & earnings, AMRX or PAHC?

Do institutionals and insiders hold more shares of AMRX or PAHC?

Which has more risk and volatility, AMRX or PAHC?

Does the media prefer AMRX or PAHC?

Summary

How does Phibro Animal Health compare to Definium Therapeutics?

Which has stronger valuation and earnings, PAHC or DFTX?

Do analysts recommend PAHC or DFTX?

Does the media favor PAHC or DFTX?

Which has more risk and volatility, PAHC or DFTX?

Do institutionals & insiders have more ownership in PAHC or DFTX?

Is PAHC or DFTX more profitable?

Summary

How does Phibro Animal Health compare to Veradermics?

Is PAHC or MANE more profitable?

Which has better earnings & valuation, PAHC or MANE?

Do analysts recommend PAHC or MANE?

Do institutionals and insiders have more ownership in PAHC or MANE?

Does the media prefer PAHC or MANE?

Summary

How does Phibro Animal Health compare to Indivior?

Which has more volatility & risk, INDV or PAHC?

Do institutionals & insiders believe in INDV or PAHC?

Does the media prefer INDV or PAHC?

Is INDV or PAHC more profitable?

Do analysts recommend INDV or PAHC?

Which has better earnings & valuation, INDV or PAHC?

Summary

How does Phibro Animal Health compare to Organon & Co.?

Does the media favor PAHC or OGN?

Which has better earnings & valuation, PAHC or OGN?

Is PAHC or OGN more profitable?

Which has more volatility and risk, PAHC or OGN?

Do insiders and institutionals have more ownership in PAHC or OGN?

Is PAHC or OGN a better dividend stock?

Do analysts prefer PAHC or OGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools